开发用于GBA1相关疾病的异构伴侣 - - 一种综合计算和实验方法
Marta Montpeyo1, Natàlia Pérez-Carmona2, Elena Cubero2
1Neurodegenerative Diseases Research Group, Vall d'Hebron Research Institute (VHIR)-Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), 08035 Barcelona, Spain.
International journal of molecular sciences
|January 11, 2025
概括
研究人员发现了新型化合物,这些化合物可以作为葡萄糖大脑化酶 (GCase) 的药理伴侣. 化合物3对治疗与GBA1相关的神经疾病,如帕金森病的治疗有希望,因为它透到大脑中.
科学领域:
- 生物化学 生物化学
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 在GBA1基因突变损害葡萄糖大脑酶 (GCase) 功能.
- GCase 缺乏与高希氏病和帕金森病风险增加有关.
- 开发有效的GCase调节器对于这些GBA1相关疾病至关重要.
研究的目的:
- 为了发现和描述GCase的新型全性药理学陪伴者.
- 在细胞模型中确定增强GCase活性和稳定性的化合物.
- 评估化合物对与GBA1相关的神经疾病的治疗潜力.
主要方法:
- 采用计算方法,包括虚拟选和结构-活动关系优化.
- 在患者衍生细胞和神经元模型中使用实验方法验证已识别的化合物.
- 进行了药理动力学研究,以评估领先候选者的脑透率.
主要成果:
- 鉴定了几种新的全性药理学陪伴者GCase.
- 化合物3显著增强了GCase活性和蛋白质水平.
- 化合物3在神经元模型中减少了有毒基质的积累,并证明了良好的脑透.
结论:
- 这项研究为开发全性GCase调节器提供了一个成功的框架.
- 化合物3是治疗包括帕金森病在内的GBA1相关疾病的有希望的主要候选者.
- 化合物3通过血脑屏障突出了其在中枢神经系统向治疗方面的潜力.
相关概念视频
Molecular Chaperones and Protein Folding
17.7K
The native conformation of a protein is formed by interactions between the side chains of its constituent amino acids. When the amino acids cannot form these interactions, the protein cannot fold by itself and needs chaperones. Notably, chaperones do not relay any additional information required for the folding of polypeptides; the native conformation of a protein is determined solely by its amino acid sequence. Chaperones catalyze protein folding without being a part of the folded protein.
The...
The...
17.7K
Allosteric Proteins-ATCase
5.7K
Binding sites linkages can regulate a protein's function. For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
5.7K
Allosteric Regulation
57.6K
Allosteric regulation of enzymes occurs when the binding of an effector molecule to a site that is different from the active site causes a change in the enzymatic activity. This alternate site is called an allosteric site, and an enzyme can contain more than one of these sites. Allosteric regulation can either be positive or negative, resulting in an increase or decrease in enzyme activity. Most enzymes that display allosteric regulation are metabolic enzymes involved in the degradation or...
57.6K
Cooperative Allosteric Transitions
7.8K
Cooperative allosteric transitions can occur in multimeric proteins, where each subunit of the protein has its own ligand-binding site. When a ligand binds to any of these subunits, it triggers a conformational change that affects the binding sites in the other subunits; this can change the affinity of the other sites for their respective ligands. The ability of the protein to change the shape of its binding site is attributed to the presence of a mix of flexible and stable segments in the...
7.8K
Amyloid Fibrils
9.2K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.2K
Ligand Binding and Linkage
4.8K
Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked. In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence...
4.8K


